Leo Wealth LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Leo Wealth LLC increased its holdings in Regeneron Pharmaceuticals by 39.6% in the second quarter, bringing its total to 1,646 shares valued at approximately $864,000.
• Several analysts have given Regeneron Pharmaceuticals a consensus target price of $817.67, with a majority recommending a buy, including a recent upgrade to a "moderate buy" by Raymond James Financial.
• The company reported strong quarterly earnings, with earnings per share of $12.89, exceeding expectations by $4.46, and revenues of $3.68 billion.

Leo Wealth LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 39.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,646 shares of the biopharmaceutical company's stock after buying an additional 467 shares during the period. Leo Wealth LLC's holdings in Regeneron Pharmaceuticals were worth $864,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of REGN. Kingswood Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after buying an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV increased its holdings in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after buying an additional 19 shares during the last quarter. Private Trust Co. NA increased its holdings in Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock valued at $104,000 after buying an additional 19 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 19 shares during the period. Finally, Cove Private Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock valued at $292,000 after acquiring an additional 20 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on REGN. Citigroup restated a "buy" rating and issued a $650.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Jefferies Financial Group lifted their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research note on Wednesday, August 27th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Weiss Ratings restated a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Finally, Rothschild & Co Redburn began coverage on Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a "buy" rating and a $890.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $569.90 on Friday. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $573.83 and a 200-day simple moving average of $565.52. The company has a market cap of $60.40 billion, a PE ratio of 14.36, a P/E/G ratio of 1.81 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $11.56 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.